Drug name - Relistor

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8552025 SALIX PHARMS Stable methylnaltrexone preparation Apr, 2024

(1 year, 6 months from now)

US10376584 SALIX PHARMS Stable pharmaceutical formulations of methylnaltrexone Apr, 2024

(1 year, 6 months from now)

US9669096 SALIX PHARMS Stable pharmaceutical formulations of methylnaltrexone Apr, 2024

(1 year, 6 months from now)

US9492445 SALIX PHARMS Peripheral opioid receptor antagonists and uses thereof Sep, 2029

(6 years from now)

US8420663 SALIX PHARMS Peripheral opioid receptor antagonists and uses thereof Sep, 2029

(6 years from now)

US8822490 SALIX PHARMS Peripheral opioid receptor antagonists and uses thereof Sep, 2029

(6 years from now)

US9180125 SALIX PHARMS Peripheral opioid receptor antagonists and uses thereof Sep, 2029

(6 years from now)

US8247425 SALIX PHARMS Peripheral opioid receptor antagonists and uses thereof Dec, 2030

(8 years from now)

Drugs and Companies using METHYLNALTREXONE BROMIDE ingredient

Treatment: Treatment of opioid-induced constipation

Dosage: SOLUTION;SUBCUTANEOUS

More Information on Dosage
Strength Dosage Availability
8MG/0.4ML (8MG/0.4ML) SOLUTION;SUBCUTANEOUS Prescription
12MG/0.6ML (12MG/0.6ML) SOLUTION;SUBCUTANEOUS Prescription
Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9180125 SALIX Peripheral opioid receptor antagonists and uses thereof Sep, 2029

(6 years from now)

US9492445 SALIX Peripheral opioid receptor antagonists and uses thereof Sep, 2029

(6 years from now)

US9724343 SALIX Peripheral opioid receptor antagonists and uses thereof Sep, 2029

(6 years from now)

US8420663 SALIX Peripheral opioid receptor antagonists and uses thereof Sep, 2029

(6 years from now)

US9314461 SALIX Oral formulations and lipophilic salts of methylnaltrexone Mar, 2031

(8 years from now)

US10307417 SALIX Oral formulations and lipophilic salts of methylnaltrexone Mar, 2031

(8 years from now)

US8524276 SALIX Oral formulations and lipophilic salts of methylnaltrexone Mar, 2031

(8 years from now)

US8956651 SALIX Oral formulations and lipophilic salts of methylnal trexone Mar, 2031

(8 years from now)

US10376505 SALIX Oral formulations and lipophilic salts of methylnaltrexone Mar, 2031

(8 years from now)

Drugs and Companies using METHYLNALTREXONE BROMIDE ingredient

Treatment: Treatment of opioid-induced constipation

Dosage: TABLET;ORAL

More Information on Dosage
Strength Dosage Availability
150MG TABLET;ORAL Prescription

availability in other generic markets.

Click on the highlighted region to filter.